Genes affecting warfarin response—interactive or additive?

Genotypes for cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) contribute significantly to the inter‐patient variability in warfarin dose requirements. These genotypes in addition to clinical factors explain approximately 50% of the dose variability in Europeans, but less in other populations. Thus, a large portion of the variability remains unexplained and has been the focus of on‐going research. Trials evaluating the clinical utility of genotype‐guided warfarin dosing have shown a benefit in Europeans, but not in an ethnically diverse cohort. Identifying and accounting for variants important in non‐European populations will likely be necessary before a benefit with genotype‐guided dosing will be realized in these populations.